Navigation Links
Anesiva Announces First Quarter 2008 Financial Results
Date:5/8/2008

SOUTH SAN FRANCISCO, Calif., May 8 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today reported financial results and accomplishments for the first quarter ended March 31, 2008 and provided an update on its commercialization activities for FDA-approved Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, as well as clinical development milestones for Adlea(TM), the company's long-acting, localized, non-opioid analgesic drug candidate.

"This is an exciting year for Anesiva as we prepare for the commercial introduction of our first product, Zingo, in the pediatric hospital setting, while pursuing a broader label to include adults," said John P. McLaughlin, chief executive officer of Anesiva. Zingo addresses the need for rapid (one to three minutes), topical local analgesia prior to peripheral IV starts and blood draws, and is approved for use in children three to 18 years of age.

There are approximately 18 million peripheral venous access procedures in children in U.S. hospitals each year. Most currently available products are impractical to use because of their long onset of action. Yet, approximately 74% of the time children must be restrained prior to venous access procedures because of the pain associated with these procedures, a fearful experience. Anesiva believes Zingo will offer healthcare providers an important alternative to address this unmet medical need.

"We've also advanced our clinical development program for Adlea in the management of acute pain following orthopedic surgery, having initiated two Phase 3 trials since the beginning of 2008," Mr. McLaughlin said. "Top-line data from both trials are anticipated by year-end."

The most common complaint among orth
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... In late 2012, Dr. Sarah Hart, of Palm Clinic ... about Appearance Medicine . Although Dr. Hart regularly teaches ... to lecture in China, and quite a different experience it ... 12 and 7 million people respectively. Interest in cosmetic facial ... in time. As Dr. Hart passed through the Fuzhou airport ...
(Date:5/16/2013)... Needham, Mass. (PRWEB) May 16, 2013 ... Bioprocessing Summit from August 19-23, 2013 at the Renaissance ... comprising the Summit provide a close-up look at the ... risk and ensuring bottom-line quality. Leaders in the ... innovative ways to produce biopharmaceuticals with greater specificity and ...
(Date:5/16/2013)... Ore. , May 16, 2013  HealthSparq, ... many of the nation,s largest regional health plans, ... America,s Health Insurance Plans (AHIP) Institute 2013 conference ... highlight survey results showing how health insurance companies ... for the consumer and marketplace demands for increased ...
(Date:5/16/2013)... Scientists at the Center for Learning and ... the California -based biopharmaceutical company Magceutics, ... for reversing memory decline in mice with Alzheimer,s Disease. ... improvement in advanced stage AD mice. The study is ... decline for advanced stage AD mice, and is also ...
Breaking Biology Technology:The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3
... Energy crop company,Ceres, Inc. announced today that ... hybrids with Range Fuels, Inc. as part,of a ... Range Fuels,commercial-scale cellulosic ethanol plant, now under construction ... While wood residues will be the primary ...
... IRVINE, Calif., Sept. 9 SectorWatch.biz announces ... the news and,driving markets today. MarketStats offers ... opportunity for investors to respond with,articles, blogs ... by visiting: http://www.SectorWatch.biz ,-- a division ...
... to be Tested on Type 2 Diabetic Volunteers, ... ORMP.OB) ( http://www.oramed.com ), a developer,of oral delivery ... with,ETI Karle Clinical Pvt. Ltd. ( http://www.etiklinical.com ), ... conduct Phase 2B clinical,trials on its oral insulin ...
Cached Biology Technology:Ceres Trials Energy Crops at Georgia Biofuel Facility 2Ceres Trials Energy Crops at Georgia Biofuel Facility 3SectorWatch.biz Issues MarketStats on Agri-Biotech Equities YGYB, GRO, SEED, MON, ADM, and BG 2Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801 2Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801 3
(Date:5/17/2013)... The State University of New Jersey, and City University ... called Visikol TM that effectively clears organisms to ... place of chloral hydrate, which is one of the ... tightly regulated by the Drug Enforcement Administration (DEA) due ... or clearing agents, are vital for viewing organisms under ...
(Date:5/17/2013)... of proteins in the brain responsible for protecting nerve ... could increase cell survival. , The discovery, made by ... in the EMBO journal with additional comment ... for stroke and other brain diseases. , The research ... a protein, known as SUMO, responsible for controlling the ...
(Date:5/17/2013)... The iCargo project (Intelligent Cargo in Efficient and Sustainable ... thanks to an improvement in the efficiency of intermodal ... assist decision making. It comprises 29 European organisations with ... management. It has a budget totalling 17,000,000 and a ... is working to specify and develop the semantic components ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3SUMO wrestling cells reveal new protective mechanism target for stroke 2New logistics services that will cut energy consumption and CO2 emissions 2
... and videos! , With their long stalks and feathery ... like their garden-variety namesakes. Perhaps because of that resemblance, scientists ... moving around like their stalkless relatives, the feather stars. ... a depth of 430 meters (1410 feet) near Grand Bahama ...
... study from the forthcoming Quarterly Review of Biology, biologists ... types of laughter ?laughter which is stimulus-driven and laughter ... occurs during everyday social interaction in response to banal ... Matthew Gervais and David Sloan Wilson. "The unstated issue ...
... Earth's landscape , The ice ages made massive changes to ... in the oceans? , Research by marine scientists reveals that ... of animals were wiped out by ice sheets scouring the ... that these ecosystems somehow dodged extinction by recolonising from nearby ...
Cached Biology News:U. of Colorado researcher identifies tracks of swimming dinosaur in Wyoming 2U. of Colorado researcher identifies tracks of swimming dinosaur in Wyoming 3Seafloor creatures destroyed by ice action during ice ages 2
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
... with Purpose -- The Varian ... the highest level of flexibility ... an affordable, easy-to-use system. The ... workstation guarantees success with today's ...
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
... 0.5-10 Kb RNA Ladder is suitable for sizing single-stranded ... glyoxal or formaldehyde agarose gels. The ladder consists of ... 3 4 6 8 and 10 kb) to simplify ... than the other bands allowing easy orientation and identification ...
Biology Products: